Select Language
Papain-like Protease
Papain-like Protease Overview
| English Name | SARS-CoV-2-3C-like-proteinase | Approved Drugs | 7 |
| Drugs in Clinical Trials | 27 | Target Synonym | Papain-like proteinase，p65 homolog，MPro，SARS-CoV-2 3CLpro，3CL-PRO，GFL，Growth factor-like peptide，Leader protein，Non-structural protein 1，Non-structural protein 10，Non-structural protein 7，Non-structural protein 6，Non-structural protein 4，Non-structural protein 3，Non-structural protein 2，Non-structural protein 11，Non-structural protein 8，Non-structural protein 9，nsp1，nsp10，nsp11，nsp2，nsp3，nsp4，nsp5，nsp6，nsp7，nsp8，nsp9，ORF1a polyprotein，SARS coronavirus main proteinase，Replicase polyprotein 1a，pp1a，PL-PRO，PL2-PRO |
| Highest Development Stage | Approved | ||
| English Name | SARS-CoV-2-3C-like-proteinase |
| Target Synonym | Papain-like proteinase，p65 homolog，MPro，SARS-CoV-2 3CLpro，3CL-PRO，GFL，Growth factor-like peptide，Leader protein，Non-structural protein 1，Non-structural protein 10，Non-structural protein 7，Non-structural protein 6，Non-structural protein 4，Non-structural protein 3，Non-structural protein 2，Non-structural protein 11，Non-structural protein 8，Non-structural protein 9，nsp1，nsp10，nsp11，nsp2，nsp3，nsp4，nsp5，nsp6，nsp7，nsp8，nsp9，ORF1a polyprotein，SARS coronavirus main proteinase，Replicase polyprotein 1a，pp1a，PL-PRO，PL2-PRO |
| Approved Drugs | 7 |
| Drugs in Clinical Trials | 27 |
| Highest Development Stage | Approved |
Papain-like Protease Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
SARS-CoV-2 (1)
- Tag
His Tag (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
PAE-C5148 | SARS-CoV-2 | E. coli | SARS-CoV-2 (COVID-19) Papain-like Protease Protein, His Tag (active enzyme) |  |  |  Add to Cart |
Total: 1
- 1
Papain-like Protease Background
New coronavirus is a single-stranded RNA positive-strand envelope type B coronavirus. Similar to the other two coronaviruses that cause SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome), its genome encodes non-structural, structural, and accessory proteins. Non-structural proteins include 3-chymotrypsin-like protease (3CLpro), papain-like protease, helicase, and RNA-dependent RNA polymerase (RNA -dependent RNA polymerase (RdRp). Structural proteins include spike glycoproteins. Papain in coronavirus is the same as 3CLpro. This enzyme operates on no less than 11 cleavage sites on the large polyprotein 1ab. Processing of polyproteins translated from viral RNA is essential. Therefore, press this The activity of this enzyme will prevent virus imitation.
Papain-like Protease Synonyms
Papain-like Protease,Replicase polyprotein 1a,ORF1a polyprotein,pp1a,1a,PL-PRO,Plpro
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ebselen | SPI-1005; SPI-3005; PZ-51; DR-3305 | Phase 3 Clinical | Daiichi Sankyo Co Ltd, Sound Pharmaceuticals Inc | Bipolar Disorder; Cochlear Diseases; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Depressive Disorder, Treatment-Resistant; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Head and Neck Neoplasms; Hearing Loss; Hearing Loss, Noise-Induced; Lung Neoplasms; Meniere Disease; Neoplasms; Nervous System Diseases; Ototoxicity; Tinnitus | Details |
| Secutrelvir | S-892216 | Phase 3 Clinical | Shionogi & Co Ltd | Coronavirus Disease 2019 (COVID-19); Renal Insufficiency | Details |
| ibuzatrelvir | PF-07817883; PF-7817883 | Phase 3 Clinical | Pfizer Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Mprosevir | WPV-01 | Phase 3 Clinical | Westlake University | Coronavirus Disease 2019 (COVID-19) | Details |
| QLS-1128 | QLS-1128 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| MIR-19 | MIR-19 | Phase 3 Clinical | St. Petersburg Scientific Research Institute of Vaccines and Sera | Coronavirus Disease 2019 (COVID-19) | Details |
| Bofutrelvir | FB-2001; DC-402234 | Phase 3 Clinical | Frontier Biotechnologies Inc, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Coronavirus Disease 2019 (COVID-19) | Details |
| Nirmatrelvir | PF-07321332 | Phase 3 Clinical | Pfizer As | Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Post-Acute COVID-19 Syndrome | Details |
| CDI-988 | CDI988 | Phase 2 Clinical | Cocrystal Pharma Inc | Coronavirus Disease 2019 (COVID-19); Norovirus Infections | Details |
| Travatrelvir | 83-0060; TRX-01 | Phase 2 Clinical | Traws Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Deusitrelvir | SHEN-211; SHEN211 | Phase 2 Clinical | Hubei JKT BioPharma Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| HS-10517 | HS-10517; HS10517 | Phase 2 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Zevotrelvir | EDP-235 | Phase 2 Clinical | Enanta Pharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Tollovir | Phase 2 Clinical | Todos Medical Ltd | Coronavirus Disease 2019 (COVID-19) | Details | |
| SNB-011 | SNB-01; SNB-011 | Phase 2 Clinical | Syneurx International (Taiwan) Corp | Coronavirus Disease 2019 (COVID-19) | Details |
| Pomotrelvir | PBI-0451 | Phase 1 Clinical | Pardes Biosciences Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| CMX-990 | CMX-990; CMX990 | Phase 1 Clinical | The Scripps Research Institute Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| WPV-02 | WPV-02; WPV02 | Phase 1 Clinical | Westlake Pharmaceuticals (Hangzhou) Co Ltd | Virus Diseases | Details |
| ISM-3312 | ISM-3312 | Phase 1 Clinical | Insilico Medicine Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Limnetrelvir | ABBV-903 | Phase 1 Clinical | Abbvie Inc | Details | |
| SAL-0133 | SAL-0133 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| SYH-2055 | SYH-2055 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| Atilotrelvir | GST-HG171 | Phase 1 Clinical | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
| ALG-097558 | ALG-097558 | Phase 1 Clinical | Aligos Therapeutics Inc, Centre for Drug Design and Discovery, Rega Institute for Medical Research | Coronavirus Disease 2019 (COVID-19) | Details |
| ASC11 | ASC-11 | Phase 1 Clinical | Ascletis Pharma Inc | Coronavirus Disease 2019 (COVID-19) | Details |
| Lufotrelvir | PF-07304814 | Phase 1 Clinical | Pfizer Inc | Coronavirus Disease 2019 (COVID-19); Virus Diseases | Details |
| GS221 | GS-221; GS221 | Clinical | Grand Pharmaceutical （China） Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Olgotrelvir | STI-1558; STI1558 | Approved | Texas A&M University | Ovydso, 奥维宁 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Zhejiang Acea Pharmaceutical Co Ltd | 2025-10-28 | Coronavirus Disease 2019 (COVID-19); Pulmonary Disease, Chronic Obstructive | Details |
| Atilotrelvir/Ritonavir | Approved | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 泰中定 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Fujian Guangsheng Zhonglin Biotechnology Co Ltd | 2023-11-23 | Coronavirus Disease 2019 (COVID-19) | Details | |
| Simnotrelvir | SIM-0417; SSD-8432; VV-934 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19) | Details | |
| Leritrelvir | RAY003; RAY-003; RAY-1216 | Approved | Guangdong Raynovent Biotech Co Ltd | 乐睿灵 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Guangdong Raynovent Biotech Co Ltd | 2023-03-23 | Acute Kidney Injury; Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency | Details |
| Simnotrelvir/Ritonavir | SIM-0417/Ritonavir; SSD-8432 / Ritonavir; SIM-0417 / Ritonavir; VV934 / Ritonavir | Approved | Jiangsu Simcere Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Wuhan Institute Of Virology, Chinese Academy Of Sciences | 先诺欣 | Mainland China | Coronavirus Disease 2019 (COVID-19) | Jiangsu Simcere Pharmaceutical Co Ltd | 2023-01-28 | Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Renal Insufficiency | Details |
| Ensitrelvir Fumaric Acid | S-217622 | Approved | Hokkaido University, Shionogi & Co Ltd | Xocova | Japan | Coronavirus Disease 2019 (COVID-19) | Shionogi & Co Ltd | 2022-11-22 | Coronavirus Disease 2019 (COVID-19); Hepatic Insufficiency; Post-Acute COVID-19 Syndrome; Renal Insufficiency | Details |
| Nirmatrelvir/Ritonavir | Approved | Pfizer Inc | Paxlovid, 瑞派乐 | EU | Coronavirus Disease 2019 (COVID-19) | Pfizer Europe Ma Eeig | 2022-01-28 | Coronavirus Disease 2019 (COVID-19); Immunologic Deficiency Syndromes; Post-Acute COVID-19 Syndrome; Postural Orthostatic Tachycardia Syndrome | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: